

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dominique P. Bridon et al.
Serial No: 10/565,900
Confirmation No: 6100
Filed: January 24, 2006
For: LONG LASTING INSULIN DERIVATIVES AND
RELATED METHODS THEREOF
Examiner: Christina Bradley
Art Unit: 1654

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being electronically filed in accordance with §1.6(a)(4) on the 4th day of September, 2009.

/Sandra Szela Congdon/
Sandra Szela Congdon, Reg. No. 60,655

Commissioner for Patents

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this supplemental Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. § 1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

PART II: Information Cited

The Applicants hereby make of record in the above-identified application the information listed on the concurrently filed form PTO/SB/08a.

The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicants hereby make the following additional information of record in the above-identified application.

The Applicants would like to bring to the Examiner's attention the enclosed European Search Report dated August 11, 2009 for European Patent Application No. 08158878.2 The references listed in the Search Report that have not been previously cited in an Information Disclosure Statement are cited herein.

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following is a concise explanation of the relevance of each non-English language reference listed on the concurrently filed form PTO/SB/08a:

European Patent No. EP 0233600 appears to be directed to insulin derivatives and methods to their preparation and their use. A computer-generated English language translation of the description is enclosed.

German Patent No. DE 2206826 appears to be directed to intramolecular crosslinked insulin derivatives and drugs on basis of these insulin derivatives as well as methods to their preparation. A computer-generated English language translation of the description is enclosed.

PART IV Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, Applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by Applicants, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

Respectfully submitted,

Dominique P. Bridon *et al.*, *Applicant*

By: Sandra Szela Congdon
Sandra Szela Congdon, Reg. No. 60,655
Attorney for Applicant
LANDO & ANASTASI, LLP
Riverfront Office Park
One Main Street
Cambridge, Massachusetts 02142
Tel. (617) 395-7000

Dated: September 4, 2009